Lifeward shares surge 24.55% premarket after strategic transaction with Oramed transferring POD platform and securing 49.9% stake.

Lifeward surged 24.55% in premarket trading following the announcement of a strategic transaction with Oramed Pharmaceuticals. Under the agreement, Lifeward acquired Oramed’s proprietary POD™ oral drug delivery platform, while Oramed secured a 49.9% beneficial ownership stake and warrants. The deal includes $47 million in financing through convertible notes and warrants, with Oramed investing $9 million in each tranche. Oramed will manage the POD™ clinical trial and retain a 4% royalty on ReWalk product sales. The partnership positions Lifeward to leverage Oramed’s biotech innovation while advancing its profitable MedTech portfolio, including $26 million in trailing ReWalk/AlterG revenue. Mark Grant, Lifeward’s CEO with deep diabetes sector experience, emphasized the transaction’s potential to drive profitability and diversify into high-growth biotech opportunities. The transaction’s scale, strategic alignment, and capital infusion likely fueled the sharp premarket rally.